Patents by Inventor Jeffrey S. Dove
Jeffrey S. Dove has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11590260Abstract: Methods for treating a bioprosthetic tissue are described herein. The methods comprise contacting the bioprosthetic tissue with at least one nucleophile and/or at least one electrophile in the presence of a catalytic system comprising at least one or a combination of a fluoride-based salt, a cesium-based salt, a potassium-based salt, a rubidium-based salt, or a carbonate-based salt. The methods may be used to alter functional groups on biological tissue which represent actual and potential calcium binding sites and also processes for cross-linking bioprosthetic tissue. Both processes may be used in conjunction with known fixative techniques, such as glutaraldehyde fixation, or may be used to replace known fixative techniques.Type: GrantFiled: March 22, 2019Date of Patent: February 28, 2023Assignee: Edwards Lifesciences CorporationInventors: Dengfeng Xu, Jeffrey S. Dove
-
Publication number: 20220241462Abstract: A bioprosthetic tissue having a reduced propensity to calcify in vivo, the bioprosthetic tissue. The bioprosthetic tissue comprises an aldehyde cross-linked and stressed bioprosthetic tissue comprising exposed calcium, phosphate or immunogenic binding sites that have been reacted with a calcification mitigant. The bioprosthetic tissue has a reduced propensity to calcify in vivo as compared to aldehyde cross-linked bioprosthetic tissue that has not been stressed and reacted with the calcification mitigant.Type: ApplicationFiled: April 18, 2022Publication date: August 4, 2022Inventors: James A. Davidson, Jeffrey S. Dove, Darin P. Dobler
-
Publication number: 20220117730Abstract: Methods for the conditioning of bioprosthetic material employ bovine pericardial membrane. A laser directed at the fibrous surface of the membrane and moved relative thereto reduces the thickness of the membrane to a specific uniform thickness and smooths the surface. The wavelength, power and pulse rate of the laser are selected which will smooth the fibrous surface as well as ablate the surface to the appropriate thickness. Alternatively, a dermatome is used to remove a layer of material from the fibrous surface of the membrane. Thinning may also employ compression. Stepwise compression with cross-linking to stabilize the membrane is used to avoid damaging the membrane through inelastic compression. Rather, the membrane is bound in the elastic compressed state through addition cross-linking. The foregoing several thinning techniques may be employed together to achieve strong thin membranes.Type: ApplicationFiled: December 23, 2021Publication date: April 21, 2022Inventors: Jeffrey S. Dove, Bin Tian, Ralph Schneider, Jeffrey S. Cohen, Ivan Jankovic, John F. Migliazza, Gregory A. Wright, James M. Young, Louis A. Campbell
-
Patent number: 11305036Abstract: A bioprosthetic tissue having a reduced propensity to calcify in vivo, the bioprosthetic tissue. The bioprosthetic tissue comprises an aldehyde cross-linked and stressed bioprosthetic tissue comprising exposed calcium, phosphate or immunogenic binding sites that have been reacted with a calcification mitigant. The bioprosthetic tissue has a reduced propensity to calcify in vivo as compared to aldehyde cross-linked bioprosthetic tissue that has not been stressed and reacted with the calcification mitigant.Type: GrantFiled: October 7, 2019Date of Patent: April 19, 2022Assignee: Edwards Lifesciences CorporationInventors: James A. Davidson, Jeffrey S. Dove, Darin P. Dobler
-
Patent number: 11213385Abstract: Methods for the conditioning of bioprosthetic material employ bovine pericardial membrane. A laser directed at the fibrous surface of the membrane and moved relative thereto reduces the thickness of the membrane to a specific uniform thickness and smoothes the surface. The wavelength, power and pulse rate of the laser are selected which will smooth the fibrous surface as well as ablate the surface to the appropriate thickness. Alternatively, a dermatome is used to remove a layer of material from the fibrous surface of the membrane. Thinning may also employ compression. Stepwise compression with cross-linking to stabilize the membrane is used to avoid damaging the membrane through inelastic compression. Rather, the membrane is bound in the elastic compressed state through addition cross-linking. The foregoing several thinning techniques may be employed together to achieve strong thin membranes.Type: GrantFiled: October 8, 2018Date of Patent: January 4, 2022Assignee: Edwards Lifesciences CorporationInventors: Jeffrey S. Dove, Bin Tian, Ralph Schneider, Jeffrey S. Cohen, Ivan Jankovic, John F. Migliazza, Gregory A. Wright, James M. Young, Louis A. Campbell
-
Publication number: 20210100931Abstract: Methods are provided herein for modifying antigenic carbohydrate epitopes within a xenographic bioprosthetic tissue by oxidation of vicinal diols to form aldehydes or acids and subsequence reductive amination of aldehydes to form stable secondary amines, or amidation or esterification of acids to form stable amides or esters. Advantageously, methods provided herein mitigate the antigenicity of the bioprosthetic tissue while leaving the overall tissue structure substantially undisturbed, and thereby enhance the durability, safety and performance of the bioprosthetic implant.Type: ApplicationFiled: December 18, 2020Publication date: April 8, 2021Inventors: Jeffrey S. Dove, Tara J. Tod
-
Patent number: 10966822Abstract: A method for manufacturing a heart valve using bioprosthetic tissue that exhibits reduced in vivo calcification. The method includes applying a calcification mitigant such as a capping agent or an antioxidant to the tissue to specifically inhibit oxidation in tissue. Also, the method can be used to inhibit oxidation in dehydrated tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the oxidation and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. In one method, tissue leaflets in assembled bioprosthetic heart valves are pretreated with an aldehyde capping agent prior to dehydration and sterilization.Type: GrantFiled: January 21, 2019Date of Patent: April 6, 2021Assignee: Edwards Lifesciences CorporationInventors: Jeffrey S. Dove, Darin P. Dobler, James A. Davidson, Gregory A. Wright
-
Publication number: 20200038554Abstract: A bioprosthetic tissue having a reduced propensity to calcify in vivo, the bioprosthetic tissue. The bioprosthetic tissue comprises an aldehyde cross-linked and stressed bioprosthetic tissue comprising exposed calcium, phosphate or immunogenic binding sites that have been reacted with a calcification mitigant. The bioprosthetic tissue has a reduced propensity to calcify in vivo as compared to aldehyde cross-linked bioprosthetic tissue that has not been stressed and reacted with the calcification mitigant.Type: ApplicationFiled: October 7, 2019Publication date: February 6, 2020Inventors: James A. Davidson, Jeffrey S. Dove, Darin P. Dobler
-
Patent number: 10434218Abstract: A treatment for bioprosthetic tissue used in implants or for assembled bioprosthetic heart valves to reduce in vivo calcification is disclosed. The method includes preconditioning, pre-stressing, or pre-damaging fixed bioprosthetic tissue in a manner that mimics the damage associated with post-implant use, while, and/or subsequently applying a calcification mitigant such as a capping agent or a linking agent to the damaged tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the damage process (service stress) and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. The linking agent will act as an elastic reinforcement or shock-absorbing spring element in the tissue structure at the site of damage from the pre-stressing.Type: GrantFiled: January 24, 2018Date of Patent: October 8, 2019Assignee: Edwards Lifesciences CorporationInventors: James A. Davidson, Jeffrey S. Dove, Darin P. Dobler
-
Publication number: 20190216978Abstract: Methods for treating a bioprosthetic tissue are described herein. The methods comprise contacting the bioprosthetic tissue with at least one nucleophile and/or at least one electrophile in the presence of a catalytic system comprising at least one or a combination of a fluoride-based salt, a cesium-based salt, a potassium-based salt, a rubidium-based salt, or a carbonate-based salt. The methods may be used to alter functional groups on biological tissue which represent actual and potential calcium binding sites and also processes for cross-linking bioprosthetic tissue. Both processes may be used in conjunction with known fixative techniques, such as glutaraldehyde fixation, or may be used to replace known fixative techniques.Type: ApplicationFiled: March 22, 2019Publication date: July 18, 2019Inventors: Dengfeng Xu, Jeffrey S. Dove
-
Patent number: 10350064Abstract: An assembly and methods for providing a contoured biological tissue are described. The assembly comprises a first plate and a second plate. The first plate is configured to receive a biological tissue. The second plate is configured to contact and compress the biological tissue received on the first plate. One or both of the first and second plates comprise a defined shape and a contoured area within the defined shape. The contoured area comprises at least first and second elevations. One or more energy sources are associated with one or both of the first and second plates. The one or more energy sources deliver energy upon compression of the biological tissue.Type: GrantFiled: April 10, 2017Date of Patent: July 16, 2019Assignee: Edwards Lifesciences CorporationInventors: Amy E. Munnelly, Jeffrey S. Dove, Minsey Lee
-
Publication number: 20190151083Abstract: A method for manufacturing a heart valve using bioprosthetic tissue that exhibits reduced in vivo calcification. The method includes applying a calcification mitigant such as a capping agent or an antioxidant to the tissue to specifically inhibit oxidation in tissue. Also, the method can be used to inhibit oxidation in dehydrated tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the oxidation and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. In one method, tissue leaflets in assembled bioprosthetic heart valves are pretreated with an aldehyde capping agent prior to dehydration and sterilization.Type: ApplicationFiled: January 21, 2019Publication date: May 23, 2019Inventors: Jeffrey S. Dove, Darin P. Dobler, James A. Davidson, Gregory A. Wright
-
Patent number: 10238771Abstract: Methods for treating a bioprosthetic tissue are described herein. The methods comprise contacting the bioprosthetic tissue with at least one nucleophile and/or at least one electrophile in the presence of a catalytic system comprising at least one or a combination of a fluoride-based salt, a cesium-based salt, a potassium-based salt, a rubidium-based salt, or a carbonate-based salt. The methods may be used to alter functional groups on biological tissue which represent actual and potential calcium binding sites and also processes for cross-linking bioprosthetic tissue. Both processes may be used in conjunction with known fixative techniques, such as glutaraldehyde fixation, or may be used to replace known fixative techniques.Type: GrantFiled: November 7, 2013Date of Patent: March 26, 2019Assignee: Edwards Lifesciences CorporationInventors: Dengfeng Xu, Jeffrey S. Dove
-
Publication number: 20190038403Abstract: Methods for the conditioning of bioprosthetic material employ bovine pericardial membrane. A laser directed at the fibrous surface of the membrane and moved relative thereto reduces the thickness of the membrane to a specific uniform thickness and smoothes the surface. The wavelength, power and pulse rate of the laser are selected which will smooth the fibrous surface as well as ablate the surface to the appropriate thickness. Alternatively, a dermatome is used to remove a layer of material from the fibrous surface of the membrane. Thinning may also employ compression. Stepwise compression with cross-linking to stabilize the membrane is used to avoid damaging the membrane through inelastic compression. Rather, the membrane is bound in the elastic compressed state through addition cross-linking. The foregoing several thinning techniques may be employed together to achieve strong thin membranes.Type: ApplicationFiled: October 8, 2018Publication date: February 7, 2019Inventors: Jeffrey S. Dove, Bin Tian, Ralph Schneider, Jeffrey S. Cohen, Ivan Jankovic, John F. Migliazza, Gregory A. Wright, James M. Young, Louis A. Campbell
-
Patent number: 10188511Abstract: A treatment for bioprosthetic tissue used in implants or for assembled bioprosthetic heart valves to reduce in vivo calcification. The method includes applying a calcification mitigant such as a capping agent or an antioxidant to the tissue to specifically inhibit oxidation in tissue. Also, the method can be used to inhibit oxidation in dehydrated tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the oxidation and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. In one method, tissue leaflets in assembled bioprosthetic heart valves are pretreated with an aldehyde capping agent prior to dehydration and sterilization.Type: GrantFiled: April 25, 2016Date of Patent: January 29, 2019Assignee: Edwards Lifesciences CorporationInventors: Jeffrey S. Dove, Darin P. Dobler, James A. Davidson, Gregory A. Wright
-
Patent number: 10092399Abstract: Methods for the conditioning of bioprosthetic material employ bovine pericardial membrane. A laser directed at the fibrous surface of the membrane and moved relative thereto reduces the thickness of the membrane to a specific uniform thickness and smoothes the surface. The wavelength, power and pulse rate of the laser are selected which will smooth the fibrous surface as well as ablate the surface to the appropriate thickness. Alternatively, a dermatome is used to remove a layer of material from the fibrous surface of the membrane. Thinning may also employ compression. Stepwise compression with cross-linking to stabilize the membrane is used to avoid damaging the membrane through inelastic compression. Rather, the membrane is bound in the elastic compressed state through addition cross-linking. The foregoing several thinning techniques may be employed together to achieve strong thin membranes.Type: GrantFiled: November 21, 2016Date of Patent: October 9, 2018Assignee: Edwards Lifesciences CorporationInventors: Jeffrey S. Dove, Bin Tian, Ralph Schneider, Jeffrey S. Cohen, Ivan Jankovic, John F. Migliazza, Gregory A. Wright, James M. Young, Louis A. Campbell
-
Publication number: 20180147323Abstract: A treatment for bioprosthetic tissue used in implants or for assembled bioprosthetic heart valves to reduce in vivo calcification is disclosed. The method includes preconditioning, pre-stressing, or pre-damaging fixed bioprosthetic tissue in a manner that mimics the damage associated with post-implant use, while, and/or subsequently applying a calcification mitigant such as a capping agent or a linking agent to the damaged tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the damage process (service stress) and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. The linking agent will act as an elastic reinforcement or shock-absorbing spring element in the tissue structure at the site of damage from the pre-stressing.Type: ApplicationFiled: January 24, 2018Publication date: May 31, 2018Inventors: James A. Davidson, Jeffrey S. Dove, Darin P. Dobler
-
Patent number: 9878068Abstract: A bioprosthetic tissue having a reduced propensity to calcify in vivo, the bioprosthetic tissue. The bioprosthetic tissue comprises an aldehyde cross-linked and stressed bioprosthetic tissue comprising exposed calcium, phosphate or immunogenic binding sites that have been reacted with a calcification mitigant. The bioprosthetic tissue has a reduced propensity to calcify in vivo as compared to aldehyde cross-linked bioprosthetic tissue that has not been stressed and reacted with the calcification mitigant.Type: GrantFiled: July 13, 2015Date of Patent: January 30, 2018Assignee: Edwards Lifesciences CorporationInventors: James A. Davidson, Jeffrey S. Dove, Darin P. Dobler
-
Publication number: 20170209263Abstract: An assembly and methods for providing a contoured biological tissue are described. The assembly comprises a first plate and a second plate. The first plate is configured to receive a biological tissue. The second plate is configured to contact and compress the biological tissue received on the first plate. One or both of the first and second plates comprise a defined shape and a contoured area within the defined shape. The contoured area comprises at least first and second elevations. One or more energy sources are associated with one or both of the first and second plates. The one or more energy sources deliver energy upon compression of the biological tissue.Type: ApplicationFiled: April 10, 2017Publication date: July 27, 2017Inventors: Amy E. Munnelly, Jeffrey S. Dove, Minsey Lee
-
Patent number: 9615922Abstract: An assembly and methods for providing a contoured biological tissue are described. The assembly comprises a first plate and a second plate. The first plate is configured to receive a biological tissue. The second plate is configured to apply a compressive force on the biological tissue that is disposed on the first plate. One or both of the first and second plates comprise a defined shape and a contoured area within the defined shape. The contoured area comprises at least first and second elevations and a continuous transition between the first and second transitions. One or more energy sources is associated with one or both of the first and second plates. The one or more energy sources delivers energy while the second plate applies the compressive force on the biological tissue disposed on the first plate.Type: GrantFiled: September 12, 2014Date of Patent: April 11, 2017Assignee: Edwards Lifesciences CorporationInventors: Amy E. Munnelly, Jeffrey S. Dove, Minsey Lee